Reardon Andrew sold LGND
November 2, 2026 · Form 4 insider transaction
Reardon Andrew sold 80 shares of Ligand Pharmaceuticals Incorporated at $314.58 per share, a transaction worth $25.2K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Disposed (sell-side)
Shares
80
Price
$314.58
Total value
$25.2K
InsiderReardon Andrew
Role—
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateNovember 2, 2026
Filing dateNovember 4, 2026
Shares owned after33,214
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1.